Y
Yoshimi Kinoshita
Researcher at Kansai Medical University
Publications - 18
Citations - 1428
Yoshimi Kinoshita is an academic researcher from Kansai Medical University. The author has contributed to research in topics: Gefitinib & Platelet activation. The author has an hindex of 7, co-authored 17 publications receiving 1303 citations.
Papers
More filters
Journal ArticleDOI
Mutations of optineurin in amyotrophic lateral sclerosis
Hirofumi Maruyama,Hiroyuki Morino,Hidefumi Ito,Hidefumi Ito,Yuishin Izumi,Hidemasa Kato,Yasuhito Watanabe,Yoshimi Kinoshita,Masaki Kamada,Masaki Kamada,Hiroyuki Nodera,Hidenori Suzuki,Osamu Komure,Shinya Matsuura,Keitaro Kobatake,Nobutoshi Morimoto,Koji Abe,Naoki Suzuki,Masashi Aoki,Akihiro Kawata,Takeshi Hirai,Takeo Kato,Kazumasa Ogasawara,Asao Hirano,Toru Takumi,Hirofumi Kusaka,Koichi Hagiwara,Ryuji Kaji,Hideshi Kawakami +28 more
TL;DR: It is shown that there are mutations in the gene encoding optineurin (OPTN), earlier reported to be a causative gene of primary open-angle glaucoma (POAG), in patients with ALS and these findings strongly suggest that OPTN is involved in the pathogenesis of ALS.
Journal ArticleDOI
Nuclear contour irregularity and abnormal transporter protein distribution in anterior horn cells in amyotrophic lateral sclerosis.
Yoshimi Kinoshita,Hidefumi Ito,Asao Hirano,Kengo Fujita,Reika Wate,Masataka Nakamura,Satoshi Kaneko,Satoshi Nakano,Hirofumi Kusaka +8 more
TL;DR: Observations suggest that dysfunctional nucleocytoplasmic transport may underlie the pathogenesis of ALS.
Journal ArticleDOI
Immunohistochemical identification of messenger RNA-related proteins in basophilic inclusions of adult-onset atypical motor neuron disease.
TL;DR: The results imply that translation attenuation could be involved in the processes of BI formation in this disorder.
Journal ArticleDOI
Aspirin reduces adverse effects of gefitinib.
Shigenori Kanazawa,Kazuyuki Yamaguchi,Yoshimi Kinoshita,Mikiko Muramatsu,Yutaka Komiyama,Shosaku Nomura +5 more
TL;DR: Results suggest that one of the mechanisms causing gefitinib-related adverse effects depends on platelet activation, and Administration of gefITinib with low-dose aspirin to lung cancer patients may prevent the development of gEFitinIB-related complications.
Journal ArticleDOI
Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Shigenori Kanazawa,Kazuyuki Yamaguchi,Yoshimi Kinoshita,Yutaka Komiyama,Mikiko Muramatsu,Shosaku Nomura +5 more
TL;DR: The finding indicated that lymphocytes were activated by gefitinib treatment, and it is deemed possible that the effect of gefITinib is induced not only by its blocking of the tyrosine kinase of epidermal growth factor receptor but also by antitumor immunity via its activation of T-cells.